



1FW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Graham Edmund KELLY

Conf. No.: 8060

Appln. No.: 10/530,176

Group Art Unit: 1615

Filed: March 9, 2006

Examiner: Unassigned

For: COMBINATION CHEMOTHERAPY COMPOSITIONS AND METHODS

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

ATTN: Office of Initial Patent Examination  
Filing Receipt Correction  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

We enclose a copy of the Official Filing Receipt for the above-identified application and request the following correction:

After the "Applicant(s)" section, and before the "Power of Attorney:" section, insert the following:

-- Assignment For Published Patent Application

Novogen Research PTY. Ltd. --.

Verification for the requested correction is indicated on the Assignment filed September 11, 2006 (a copy of which is attached hereto).

Respectfully submitted,

Gordon Kit

Registration No. 30,764

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: September 11, 2006



OCT 15 2006  
SEP 11 2006  
PATENT AND TRADEMARK OFFICE

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/530,176	03/09/2006	1615	1830		8	19	7

## CONFIRMATION NO. 8060

23373  
SUGHRUE MION, PLLC  
2100 PENNSYLVANIA AVENUE, N.W.  
SUITE 800  
WASHINGTON, DC 20037

## FILING RECEIPT



\*OC000000018746407\*

Date Mailed: 05/11/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Graham Edmund Kelly, Northbridge, AUSTRALIA;

*ASSIGNMENT FOR Published Patent Application  
NOVOGEN RESEARCH PTY, LTD.*

Power of Attorney: The patent practitioners associated with Customer Number 23373.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/AU03/01296 10/02/2003

## Foreign Applications

## Acceptable Request to Retrieve Priority Application Received?

AUSTRALIA 2002951833 10/02/2002

NO

Projected Publication Date: 08/17/2006

Non-Publication Request: No

Early Publication Request: No

## Title

Combination chemotherapy compositions and methods

Preliminary Class

514

## PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

### LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject

matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**DEED OF ASSIGNMENT**

This assignment dated this 6 day of May 2005.

**BETWEEN** **Graham Edmund KELLY**  
of 17 Peel Street  
Kirribilli NSW 2061  
AUSTRALIA

hereinafter referred to as the Assignor of the first part.

**AND** **NOVOGEN RESEARCH PTY LIMITED**  
of 140 Wicks Road  
North Ryde NSW 2113  
AUSTRALIA

hereinafter referred to as the Assignee of the second part.

WHEREAS the Assignor is the inventor for an invention entitled "Combination chemotherapy compositions and methods" the subject of International Patent Application No. PCT/AU03/01296 filed on 2 October 2003, based on Australian Provisional Patent Application No. 2002951833 filed on 2 October 2002 (hereinafter referred to as "the Applications").

This Assignment Witnesses that, in consideration of TEN DOLLARS (\$10.00) receipt of which is acknowledged by the Assignor, the Assignor hereby assigns transfers and sets over to the Assignee the whole right title and interest in the invention described in the Applications and in the whole right title and interest in the Applications including but not limited to the right, either presently existing or at any time in the future, to make application for and obtain patents or any other form of legal protection in Australia, Canada, China, Europe, Hong Kong, Israel, Japan, New Zealand, Mexico, Norway, Singapore, United States or any other State in respect of the invention, including the right to file further applications for patent, and claim priority based on the Applications.

The Assignor shall at the expense and request of the Assignee execute all such documents and do all such acts and things which may be necessary to vest in the Assignee absolutely the Application and Invention described in the Application and shall at the request and expense of the Assignee execute all such documents and do all such acts and things as the Assignee may reasonably require for assisting in the prosecution of the Applications or any further filed applications based thereon.

In witness thereof, the parties hereto have executed the Assignment effective the date first above mentioned.

## Graham Edmund KELLY

whose signature appears opposite hereto:

## Graham Edmund KELLY

Place:

At the end

Witness:

For and on behalf of  
**NOVOGEN RESEARCH PTY LTD**  
by its authorised officer(s) whose  
signature(s) appear opposite hereto:

Name: \_\_\_\_\_

Title:

Place:

Witness:

**DEED OF ASSIGNMENT**

This assignment dated this 24<sup>th</sup> day of May 2005.

**BETWEEN** **Graham Edmund KELLY**  
of 17 Peel Street  
Kirribilli NSW 2061  
AUSTRALIA

hereinafter referred to as the Assignor of the first part.

**AND** **NOVOGEN RESEARCH PTY LIMITED**  
of 140 Wicks Road  
North Ryde NSW 2113  
AUSTRALIA

hereinafter referred to as the Assignee of the second part.

WHEREAS the Assignor is the inventor for an invention entitled "Combination chemotherapy compositions and methods" the subject of International Patent Application No. PCT/AU03/01296 filed on 2 October 2003, based on Australian Provisional Patent Application No. 2002951833 filed on 2 October 2002 (hereinafter referred to as "the Applications").

This Assignment Witnesses that, in consideration of TEN DOLLARS (\$10.00) receipt of which is acknowledged by the Assignor, the Assignor hereby assigns transfers and sets over to the Assignee the whole right title and interest in the invention described in the Applications and in the whole right title and interest in the Applications including but not limited to the right, either presently existing or at any time in the future, to make application for and obtain patents or any other form of legal protection in Australia, Canada, China, Europe, Hong Kong, Israel, Japan, New Zealand, Mexico, Norway, Singapore, United States or any other State in respect of the invention, including the right to file further applications for patent, and claim priority based on the Applications.

The Assignor shall at the expense and request of the Assignee execute all such documents and do all such acts and things which may be necessary to vest in the Assignee absolutely the Application and Invention described in the Application and shall at the request and expense of the Assignee execute all such documents and do all such acts and things as the Assignee may reasonably require for assisting in the prosecution of the Applications or any further filed applications based thereon.

In witness thereof, the parties hereto have executed the Assignment effective the date first above mentioned.

**Graham Edmund KELLY**

whose signature appears opposite hereto:

Graham Edmund KELLY

Place:

Witness:

For and on behalf of  
**NOVOGEN RESEARCH PTY LTD**  
by its authorised officer(s) whose  
signature(s) appear opposite hereto:

*Deanne*

Name: RONALD LEA GRANT

Title: SECRETARY

SYDNEY AUSTRALIA.

Place:

*Jane Illes*

Witness: JANE ILLES.